Scientific research drives innovation at Novartis. Our researchers work to push the boundaries of science, broaden our understanding of diseases and develop novel products with significant benefits for patients. We are focusing on faulty molecular pathways and therapeutic areas where we see the greatest unmet medical need and believe the scientific tools to address these needs are within reach.
The Novartis Institutes for BioMedical Research (NIBR) is the innovation engine of Novartis. More than 6 000 scientists and physicians prioritize work based on areas of greatest patient need and scientific understanding of disease.
NIBR takes a unique approach to pharmaceutical research. At the earliest stages, research priorities are determined by patient need and disease understanding.
At NIBR, physician-scientists are breaking down the boundaries between research and clinical practice. We use Proof-of-Concept clinical trials (small-scale studies used to get an early read on a drug’s safety and effectiveness) to help us find and advance the most promising drug candidates.
We believe we can better answer the demand for safer, more effective medicines by keeping our sights on both the science and the patient.